Open access
Aug 2026
Schizophrenia Spectrum Biomarkers Consortium: Establishment of a Biorepository for the Discovery of Quantitative Fluid Biomarkers
Abstract Background and Hypothesis Schizophrenia spectrum disorders (SSDs) produce severe symptoms, disability, and premature mortality, but only partially effective symptomatic treatments exist. Treatment development is impeded by lack of insight into disease mechanisms or objective biomarkers for clinical trials. Adv...
Mohini Ranganathan, Susan G. Jakob, F. Cerrato et al.
· Schizophrenia bulletin · 0 citations